E-Mail
IMAGE: Novel cancer immunotherapy approach inverts a missing gene copy into an immune cell-activating signal. view more
Credit: Elizabeth Cook
Researchers developed a prototype for a new cancer immunotherapy that uses engineered T cells to target a genetic alteration common among all cancers. The approach, which stimulates an immune response against cells that are missing one gene copy, called loss of heterozygosity (LOH), was developed by researchers at the Ludwig Center, Lustgarten Laboratory and the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center.
Genes have two alleles, or copies, with one copy inherited from each parent. Cancer-related genetic alterations commonly involve the loss of one of these gene copies.
Two of the three research studies led by Jacqueline Douglass, M.D., Ph.D. candidate at the Johns Hopkins University School of Medicine and Emily Han-Chung Hsiue, M.D., Ph.D., postdoctoral fellow at Johns Hopkins report on a precision medicine immunotherapy approach that specifically kills cancer cells by targeting mutant protein fragments presented as antigens on the cancer cell surface.
Although common across cancer types, p53 mutations have not been successfully targeted with drugs. Genetic alterations in tumor suppressor genes often resulted in their functional inactivation. Traditional drugs are aimed at inhibiting proteins. Inhibiting an already inactivated tumor suppressor gene protein in cancer cells, therefore, is not a feasible approach, says Hsiue, lead author on the
BVI International Arbitration Centre Expands Global Representation, Welcomes Dr. John J. Maalouf to Arbitration Panel
February 22, 2021 13:47 ET | Source: Maalouf Ashford & Talbot Maalouf Ashford & Talbot
BVI IAC reaffirms commitment to diverse representation of the international business community
NEW YORK, NY, Feb. 22, 2021 (GLOBE NEWSWIRE) via NewMediaWire The British Virgin Islands International Arbitration Centre (BVI IAC), an independent not-for-profit institution serving the demands for dispute resolution in the international business community, today announced that Dr. John J. Maalouf has joined its arbitration panel. Dr. Maaloufis one of 10 arbitrators welcomed by the BVI IAC through its latest empanelment process.
Dr. Maalouf is Senior Partner of the international law firm Maalouf Ashford & Talbot, LLP. His practice is focused on international trade and finance law, international arbitration, mediation and alternative disput
Amazon, in its application, informed the NCLT that it has filed an SLP before the Supreme Court against an order of the Division Bench of the Delhi High Court, dated February 8.
Amazon has also asked for restraining Future Retail from taking any steps to further the deal with Reliance until the final award is granted in the Singapore arbitration